166 related articles for article (PubMed ID: 37456237)
1. Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment.
Dai G; He L; Yan Q; Li Y; Huang Y; Li B; Wang G
Front Oncol; 2023; 13():1167516. PubMed ID: 37456237
[TBL] [Abstract][Full Text] [Related]
2. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review.
Piao MN; Ma XT; Tankere P; Liam CK; Li JL; Wang JP
Ann Transl Med; 2022 Sep; 10(18):1030. PubMed ID: 36267791
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review.
Wu S; Wu S; Liao X; Zhou C; Qiu F; Wang C; Zhong W
Front Immunol; 2023; 14():1274937. PubMed ID: 37936698
[TBL] [Abstract][Full Text] [Related]
5. Dramatic Response of Pulmonary Sarcomatoid Carcinoma to Nivolumab Combined with Anlotinib: A Case Report.
Jin C; Yang B
Case Rep Oncol; 2020; 13(2):601-605. PubMed ID: 32595469
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib-a case report.
Li YF; Zhao XF; Tian Y; Xiao XY; Yan CY; Shen H
Front Genet; 2022; 13():949989. PubMed ID: 35938033
[TBL] [Abstract][Full Text] [Related]
7. Case report: Successful treatment of advanced pulmonary sarcomatoid carcinoma with BUBIB
Huang N; Qu T; Zhang C; Li J
Front Oncol; 2024; 14():1269148. PubMed ID: 38414747
[TBL] [Abstract][Full Text] [Related]
8. A case report: A new promising treatment for pulmonary sarcomatoid carcinoma - Tislelizumab and Anlotinib combined with local radiotherapy.
Cai R; Liu Y; Sha H; Yu J; Fang Y; Zhou G; Shen B
Heliyon; 2023 Nov; 9(11):e21902. PubMed ID: 38027958
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review.
Wen Y; Dong Y; Yi L; Yang G; Xiao M; Li Q; Zhao C; Ye D; Yao Y
Front Oncol; 2023; 13():1241475. PubMed ID: 37920159
[TBL] [Abstract][Full Text] [Related]
10. Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report.
Chen P; Yu M; Zhang JL; Chen WY; Zhu L; Song Y; Jiang CY; Zhang S
World J Clin Cases; 2020 Jul; 8(13):2876-2884. PubMed ID: 32742998
[TBL] [Abstract][Full Text] [Related]
11. Sintilimab combined with anlotinib as first-line treatment for advanced sarcomatoid carcinoma of head and neck: a case report and literature review.
Wang L; Huang Y; Sun X
Front Oncol; 2024; 14():1362160. PubMed ID: 38725630
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of advanced pulmonary sarcomatoid carcinoma with the PD-1 inhibitor toripalimab: A case report.
Jiao Y; Liu M; Luo N; Guo H; Li J
Oral Oncol; 2021 Jan; 112():104992. PubMed ID: 32943323
[TBL] [Abstract][Full Text] [Related]
13. Anlotinib Combined With Chemotherapy for Recurrence of Pulmonary Sarcomatoid Cancer Previously Surgically Treated: A Case Report and Literature Review.
Li J; Liang H; He J; Sui X; Qin Y
Front Oncol; 2021; 11():639168. PubMed ID: 34046343
[TBL] [Abstract][Full Text] [Related]
14. KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China.
Li Q; Zhou Q; Zhao S; Wu P; Shi P; Zeng J; Xiong X; Chen H; Kittaneh M; Bravaccini S; Zanoni M; Zhou C; Zhang J
Transl Lung Cancer Res; 2022 Oct; 11(10):2136-2147. PubMed ID: 36386464
[TBL] [Abstract][Full Text] [Related]
15. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC.
Chu T; Zhong R; Zhong H; Zhang B; Zhang W; Shi C; Qian J; Zhang Y; Chang Q; Zhang X; Dong Y; Teng J; Gao Z; Qiang H; Nie W; Zhao Y; Han Y; Chen Y; Han B
J Thorac Oncol; 2021 Apr; 16(4):643-652. PubMed ID: 33524601
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with
Qi W; Xi D; Bai Y; Liu L; Ma Y; Yin Z; Chen H
Front Pharmacol; 2023; 14():1026135. PubMed ID: 36713848
[No Abstract] [Full Text] [Related]
17. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
Wang P; Fang X; Yin T; Tian H; Yu J; Teng F
Front Oncol; 2021; 11():628124. PubMed ID: 33791214
[TBL] [Abstract][Full Text] [Related]
18. Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification.
Liu Y; Long L; Liu J; Zhu L; Luo F
Front Oncol; 2021; 11():749682. PubMed ID: 34692530
[TBL] [Abstract][Full Text] [Related]
19. Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4-ALK fusion: A case report.
Wang M; Gong Y; Cheng Y; Yang L; Wang W; Lei X
Oncol Lett; 2022 Oct; 24(4):343. PubMed ID: 36072009
[TBL] [Abstract][Full Text] [Related]
20. Treatment Response to Immunotherapy After Crizotinib Resistance in a Patient With Pulmonary Sarcomatoid Carcinoma Harboring MET Exon 14 Skipping Mutation: A Case Report.
Gu L; Wei X; Zhang Z; Heng W
Clin Med Insights Oncol; 2022; 16():11795549211067185. PubMed ID: 35110965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
